Second Quarter 2026
Filed Aug 7, 2026Entera Announces Second Quarter 2026 Financial Results and Business Updates
The quarter included FDA alignment on the EB613 registrational Phase 3 plan and an oversubscribed private placement providing approximately $275.0 million in gross proceeds, while research and development expense and net loss increased as the company prepared for Phase 3 and advanced the OPKO collaboration.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Cash and cash equivalentsother | $11.3 million | – | – |
| Restricted cashother | $7.1 million | – | – |
| Research and development expensesother | $3.2 million | – | – |
| General and administrative expensesother | $1.4 million | – | – |
| Net lossother | $7.3 million | – | – |
| Net loss per ordinary share, basic and dilutedother | $0.14 per ordinary share (basic and diluted) | – | – |
Late 2026 through 2030 outlook
- NoteEntera plans to initiate the registrational Phase 3 study in late 2026, with topline results anticipated in the second half of 2028.
- NoteEntera and OPKO intend to file an Investigational New Drug (IND) application for EB612 in the first half of 2027.
- NoteThe net proceeds are anticipated to fully support the Phase 3 registrational program of EB613 through the anticipated submission of NDA to the FDA, advance EB612 into the clinic in collaboration with OPKO and extend the Company’s cash runway into 2030.
- NoteOn a pro forma basis, following the closing of the July 2026 private placement in which the Company received aggregate gross proceeds of approximately $275.0 million, the Company’s cash resources are expected to be sufficient to fully fund the planned Phase 3 registrational program of EB613 through topline results and the anticipated submission of an NDA to the FDA and to support the Company’s operations into 2030.
What drove it
- The FDA accepted Entera’s plan to conduct a single, randomized, double-blind, placebo-controlled Phase 3 trial in approximately 750 postmenopausal women with osteoporosis to support a potential NDA submission for EB613.
- Single-tablet EB613 demonstrated a pharmacokinetic and pharmacodynamic profile comparable to multi-tablet EB613 and Forteo® in comparative Phase 1 data presented at ENDO 2026.
- Research and development expense increased primarily due to increased materials, production and other costs related to preparation of the EB613 Phase 3 program and activities under the OPKO collaboration.
- EB612 preclinical data across three models showed robust bioavailability and rapid, sustained increases in serum calcium lasting approximately three days.
- EB618 non-human primate data showed robust bioavailability, dose-proportional systemic exposure and dose-proportional effects on postprandial blood glucose levels.
Concerns
- Net loss was $7.3 million, compared with $2.7 million for the three months ended June 30, 2025.
- The increase in net loss was primarily driven by a $2.7 million non-cash fair value remeasurement of pre-funded warrants issued in the April 2026 private placement and classified as a financial liability.
- EB613 Phase 3 initiation is planned for late 2026, with topline results anticipated in the second half of 2028.
- The Company expects to evaluate initiation of EB618 clinical development pursuant to analysis of Phase 1 SAD/MAD studies of subcutaneous injectable OXM being conducted by OPKO.
What to watch
- Initiation of the EB613 registrational Phase 3 study in late 2026.
- Topline EB613 Phase 3 results anticipated in the second half of 2028.
- An IND filing for EB612 intended in the first half of 2027.
- New Phase 2 analysis of EB613 scheduled for plenary poster presentation at the ASBMR 2026 Annual Meeting taking place October 9–12, 2026.
- Analysis of OPKO’s Phase 1 SAD/MAD studies of subcutaneous injectable OXM in relation to potential EB618 clinical development.
Balance sheet and cash flow
- Cash and cash equivalents were $11.3 million as of June 30, 2026.
- Restricted cash was $7.1 million, primarily designated to fund the OPKO collaboration.
- Subsequent to quarter end, the July 2026 private placement provided gross proceeds of approximately $275.0 million before deducting placement agent fees and offering expenses.
- In April 2026, Entera announced a private placement led by BVF for approximately $10.0 million in gross proceeds, with the potential for up to $24.5 million in total proceeds upon full exercise of accompanying five-year warrants.
Analysis
Entera reported a development-focused second quarter marked by regulatory progress and financing rather than commercial performance. The FDA accepted the company’s plan for a single randomized, double-blind, placebo-controlled Phase 3 trial in approximately 750 postmenopausal women with osteoporosis for EB613. The company plans to initiate the registrational study in late 2026, with topline results anticipated in the second half of 2028. The proposed NDA package is expected to include a scientific bridge analysis with Forteo® under the 505(b)(2) pathway and a transiliac crest bone biopsy sub-study in a subset of patients.
Operating expenses increased as Entera readied EB613 for Phase 3 and worked under the OPKO collaboration. Research and development expenses were $3.2 million, compared with $1.5 million in the prior-year quarter, with the company citing increased materials, production and other preparation costs for the EB613 Phase 3 program as well as OPKO collaboration activities. General and administrative expenses were $1.4 million, compared with $1.1 million. Net loss was $7.3 million, or $0.14 per ordinary share basic and diluted, versus $2.7 million, or $0.06 per ordinary share basic and diluted. Management said the increase was primarily driven by a $2.7 million non-cash fair value remeasurement of pre-funded warrants.
Liquidity changed materially after quarter end. Cash and cash equivalents stood at $11.3 million at June 30, 2026, with $7.1 million of restricted cash primarily designated for the OPKO collaboration. In July 2026, Entera announced an oversubscribed private placement providing gross proceeds of approximately $275.0 million before fees and expenses. The company stated that the net proceeds are anticipated to support the EB613 Phase 3 registrational program through anticipated NDA submission, advance EB612 into the clinic with OPKO, and extend cash runway into 2030.
Pipeline execution remains the central determinant of the next stages. Single-tablet EB613 Phase 1 data presented at ENDO 2026 were described as comparable with multi-tablet EB613 and Forteo® on pharmacokinetic and pharmacodynamic profiles. EB612 remains in IND-enabling work, with Entera and OPKO intending to file an IND in the first half of 2027. EB618 produced preclinical non-human primate PK/PD data, but the company expects to evaluate clinical initiation based on analysis of OPKO’s Phase 1 SAD/MAD studies of subcutaneous injectable OXM.
The key near-term items are the planned EB613 Phase 3 initiation in late 2026, the EB612 IND timing in the first half of 2027, and further EB613 data presentation at ASBMR 2026. The filing provides no revenue, margin, operating-income, cash-flow, debt, or revenue guidance figures, consistent with the company’s clinical-stage profile.
Management, verbatim
The capital raising transaction we announced on July 27, 2026, led by BVF is transformational for Entera.
Miranda Toledano, Chief Executive Officer of Entera
Not in the filing
stated, not guessed- Total revenue
- Revenue by segment
- Gross profit and gross margin
- Operating income or loss
- Non-GAAP operating income or loss
- Non-GAAP net income or loss
- Non-GAAP EPS
- Operating cash flow
- Free cash flow
- Debt
- Share repurchases
- Dividends
- Capital expenditures
- Prior-quarter comparisons for reported financial metrics
- Revenue guidance
- Gross-margin guidance
- Operating-expense guidance
- Tax-rate guidance
- Previous-quarter outlook for comparison
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.